Switch theme
Sign up to access all valuation multiples
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
1987
68
LTM Revenue $174M
LTM EBITDA $68.8M
$1.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Ligand Pharmaceuticals has a last 12-month revenue of $174M and a last 12-month EBITDA of $68.8M.
In the most recent fiscal year, Ligand Pharmaceuticals achieved revenue of $167M and an EBITDA of $40.8M.
Ligand Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Ligand Pharmaceuticals valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $131M | $167M | XXX | XXX | XXX |
| Gross Profit | $143M | $121M | XXX | XXX | XXX |
| Gross Margin | 109% | 72% | XXX | XXX | XXX |
| EBITDA | $100.0M | $40.8M | XXX | XXX | XXX |
| EBITDA Margin | 76% | 24% | XXX | XXX | XXX |
| Net Profit | -$33.4M | $52.2M | XXX | XXX | XXX |
| Net Margin | -25% | 31% | XXX | XXX | XXX |
| Net Debt | $31.7M | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Ligand Pharmaceuticals's stock price is $107.
Ligand Pharmaceuticals has current market cap of $2.1B, and EV of $1.8B.
See Ligand Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.8B | $2.1B | XXX | XXX | XXX | XXX | $5.84 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Ligand Pharmaceuticals has market cap of $2.1B and EV of $1.8B.
Ligand Pharmaceuticals's trades at 10.4x LTM EV/Revenue multiple, and 26.2x LTM EBITDA.
Analysts estimate Ligand Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Ligand Pharmaceuticals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.8B | XXX | XXX | XXX |
| EV/Revenue | 10.8x | XXX | XXX | XXX |
| EV/EBITDA | 44.2x | XXX | XXX | XXX |
| P/E | -509.0x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 23.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpLigand Pharmaceuticals's NTM/LTM revenue growth is 17%
Ligand Pharmaceuticals's revenue per employee for the last fiscal year averaged $2.5M, while opex per employee averaged $2.0M for the same period.
Over next 12 months, Ligand Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Ligand Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Ligand Pharmaceuticals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 27% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -59% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 41% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $2.5M | XXX | XXX | XXX | XXX |
| Opex per Employee | $2.0M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 47% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 13% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 80% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ligand Pharmaceuticals acquired XXX companies to date.
Last acquisition by Ligand Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Ligand Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Ligand Pharmaceuticals founded? | Ligand Pharmaceuticals was founded in 1987. |
| Where is Ligand Pharmaceuticals headquartered? | Ligand Pharmaceuticals is headquartered in United States of America. |
| How many employees does Ligand Pharmaceuticals have? | As of today, Ligand Pharmaceuticals has 68 employees. |
| Who is the CEO of Ligand Pharmaceuticals? | Ligand Pharmaceuticals's CEO is Mr. Todd C. Davis. |
| Is Ligand Pharmaceuticals publicy listed? | Yes, Ligand Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Ligand Pharmaceuticals? | Ligand Pharmaceuticals trades under LGND ticker. |
| When did Ligand Pharmaceuticals go public? | Ligand Pharmaceuticals went public in 1995. |
| Who are competitors of Ligand Pharmaceuticals? | Similar companies to Ligand Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Ligand Pharmaceuticals? | Ligand Pharmaceuticals's current market cap is $2.1B |
| What is the current revenue of Ligand Pharmaceuticals? | Ligand Pharmaceuticals's last 12-month revenue is $174M. |
| What is the current EBITDA of Ligand Pharmaceuticals? | Ligand Pharmaceuticals's last 12-month EBITDA is $68.8M. |
| What is the current EV/Revenue multiple of Ligand Pharmaceuticals? | Current revenue multiple of Ligand Pharmaceuticals is 10.4x. |
| What is the current EV/EBITDA multiple of Ligand Pharmaceuticals? | Current EBITDA multiple of Ligand Pharmaceuticals is 26.2x. |
| What is the current revenue growth of Ligand Pharmaceuticals? | Ligand Pharmaceuticals revenue growth between 2023 and 2024 was 27%. |
| Is Ligand Pharmaceuticals profitable? | Yes, Ligand Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
